July 23 (Reuters) - The U.S. Food and Drug
Administration has extended its review of GSK's blood
cancer drug Blenrep as a combination treatment, the company said
on Wednesday.
The health regulator has set an action date of October 23
which provides the FDA with time to review additional
information provided in support of the application.
(Reporting by Sneha S K and Sriparna Roy in Bengaluru; Editing
by Sriraj Kalluvila)